Correlation between Suppression of Tumorigenicity-2 with Left Ventricular Geometry, Left Ventricular Ejection Fraction and Quality of Life in Systolic Heart Failure Patients

Johan Gunadi, Starry Homenta Rampengan, Janry Antonius Pangemanan, Agnes Lucia Panda, Nancy Lampus, Hasjim Hasbullah


BACKGROUND: Heart failure (HF) is a clinical syndrome caused by structural or functional cardiac disorders and is the final stage of every heart disease, marked by decreased functional capacity and patients’ quality of life (QoL). Suppression of tumorigenicity-2 (ST2) is a biomarker depicting heart fibrosis and remodeling that altered left ventricular geometry, which in turn decreases left ventricular contractility, decreases functional capacity, and ultimately affects the QoL of the HF patient.

METHODS: An observational study was conducted with a cross-sectional approach involving 60 patients with systolic heart failure. Left ventricular geometry, left ventricular ejection fraction (LVEF), ST2 level, and other biomarkers were examined, continued by QoL assessment.

RESULTS: The ST2 level (33.25±23.55 ng/mL) was negatively correlated with LVEF (r=-0.257; p=0.024) and was positively correlated with QoL (r=0.255; p=0.05). The LVEF was negatively correlated with QoL (r=-0.224; p=0.031). However, no significant correlation was found between left ventricular geometry with ST2 level or patients’ QoL.

CONCLUSION: Elevated ST2 levels are correlated with decreased LVEF and worse QoL in systolic heart failure subjects. Therefore, ST2 together with LVEF can be used as prognostic tools for patients with HF.

KEYWORDS: heart failure, ST2, left ventricular geometry, left ventricular ejection fraction, quality of life

Full Text:



Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016; 133: e38- 360, CrossRef.

Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292: 344-50, CrossRef.

Kemenkes RI. Riset Kesehatan Dasar 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan RI; 2013, article.

Kemenkes RI. Situasi Kesehatan Jantung. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia; 2014, article.

Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol. 2014; 10: 525-39, CrossRef.

Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, et al. Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. Circ Heart Fail. 2013; 6: 1172-9, CrossRef.

Lilly LS. Pathophysiology of heart disease: a collaborative project of medical students and faculty. 6th edition. Philadelphia: Wolters Kluwer; 2016, NLMID.

Villacorta H, Maisel AS. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016; 106: 145-52, CrossRef.

Rampengan SH, Prihartono J, Siagian M, Immanuel S. The effect of enhanced external counterpulsation therapy and improvement of functional capacity in chronic heart failure patients: a randomized clinical trial. Acta Medica Indones. 2015; 47: 275-82, article.

Kusuma DY, Shatri H, Alwi I, Abdullah M. Validity and reliability studies of the Indonesian version of the Minnesota Living with Heart Failure Questionnaire (MLHFQ): uality of Life Questionnaire for Patients with Chronic Heart Failure. Acta Medica Indones. 2019; 51: 26-33, article.

Dieplinger B, Egger M, Gegenhuber A, Haltmayer M, Mueller T. Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta Int J Clin Chem. 2015; 451: 310-5, CrossRef.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertensionThe Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159-219, CrossRef.

Santos J, Brofman P. Six-minute walk test and quality-of-life in heart failure A correlative study with a Brazilian sample. Rev Insuf Card. 2008; III: 72-5, article.

Lavie CJ, Patel DA, Milani RV, Ventura HO, Shah S, Gilliland Y. Impact of echocardiographic left ventricular geometry on clinical prognosis. Prog Cardiovasc Dis. 2014; 57: 3-9, CrossRef.

Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi OM, Sliwa K. The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects. J Hum Hypertens. 2014; 28: 432-7, CrossRef.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: A Report ofthe American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136: e137-61, CrossRef.

Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail. 2013; 6: 1206-13, CrossRef.

AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, et al. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J Am Heart Assoc. 2017 18;6: e004382, CrossRef.

Bahuleyan CG, Alummoottil GK, Abdullakutty J, Lordson AJ, Babu S, Krishnakumar VV, et al. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction – A multicenter study. Indian Heart J. 2018; 70: S79-84, CrossRef.

Bussoni MF, Guirado GN, Roscani MG, Polegato BF, Matsubara LS, Bazan SGZ, et al. Diastolic function is associated with quality of life and exercise capacity in stable heart failure patients with reduced ejection fraction. Braz J Med Biol Res. 2013; 46: 803-8, CrossRef.


Indexed by:






The Prodia Education and Research Institute